Decoy Therapeutics grants director 2,000 shares
Decoy Therapeutics director Jonathan I. Lieber received a 2,000‑share restricted stock grant vesting in 2027, modestly increasing his adjusted ownership.
Rhea-AI Filing Summary
Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Lieber Jonathan I reported acquisition or exercise transactions in this Form 4 filing.
Decoy Therapeutics Inc. (DCOY) director Jonathan I. Lieber received a grant of 2,000 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. The award vests 100 percent on August 30, 2027, and brings his directly held beneficial ownership to 2,002 shares, adjusted for reverse stock splits effective on August 15, 2025 and March 6, 2026. No Rule 10b5-1 plan is reported for this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,000 shares
Grant/Award
1 txn
Insider
Lieber Jonathan I
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 2,002 shares (Direct)
Footnotes (2)
- F1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
- F2. Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Key Figures
Restricted stock grant: 2,000 shares
Post-transaction holdings: 2,002 shares
Vesting date: August 30, 2027
+3 more
6 metrics
Restricted stock grant
2,000 shares
Grant of restricted common stock on August 31, 2026 under the 2026 Equity Incentive Plan
Post-transaction holdings
2,002 shares
Shares beneficially owned directly by Jonathan I. Lieber after the grant, split-adjusted
Vesting date
August 30, 2027
Date when 100 percent of the 2,000 restricted shares will vest
Reverse stock split effective date 1
August 15, 2025
First reverse stock split reflected in adjusted beneficial ownership
Reverse stock split effective date 2
March 6, 2026
Second reverse stock split reflected in adjusted beneficial ownership
Grant price per share
$0.00
Reported transaction price per share for the restricted stock award
Key Terms
Restricted stock, Equity Incentive Plan, reverse stock splits, beneficially owned
4 terms
Restricted stock financial
"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Equity Incentive Plan financial
"granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
reverse stock splits financial
"adjusted to reflect the reverse stock splits effective on August 15, 2025"
A reverse stock split is when a company combines multiple existing shares into fewer higher-priced shares—like trading four small slices of a pie for one larger slice. It doesn’t change the overall value of an investor’s holdings immediately, but it raises the per-share price and can matter to investors because it can affect market perception, stock exchange listing eligibility, and trading liquidity, and it changes share counts used in investor metrics.
beneficially owned financial
"Shares beneficially owned following the transaction have been adjusted"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
What insider transaction did DCOY director Jonathan I. Lieber report?
He reported an acquisition of 2,000 shares of restricted common stock on August 31, 2026 as a grant or award under Decoy Therapeutics Inc.'s 2026 Equity Incentive Plan, with no cash price per share indicated.
Was Jonathan I. Lieber’s DCOY stock grant made under a Rule 10b5-1 trading plan?
No. The filing's Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote indicating a trading plan. The grant is reported simply as a grant, award, or other acquisition of restricted stock.
How were prior reverse stock splits reflected in Jonathan I. Lieber’s DCOY holdings?
A footnote states that shares beneficially owned following the transaction have been adjusted to reflect reverse stock splits that became effective on August 15, 2025 and March 6, 2026, so the reported 2,002 shares are on a split-adjusted basis.
AI-generated analysis. How Rhea-AI works. Not financial advice.
